Literature DB >> 2235671

Pharmacokinetics and pharmacodynamics of heparin during hemodialysis: interpatient and intrapatient variability.

R J Kandrotas1, P Gal, J B Douglas, J Deterding.   

Abstract

Heparin pharmacokinetics and pharmacodynamics were studied in 17 patients undergoing hemodialysis, once a week for 4 weeks in order to evaluate intrapatient variability over time. A single bolus injection of heparin was administered directly into the circulation immediately prior to the start of hemodialysis in doses ranging from 3000 to 12,000 U. Blood samples were obtained to determine activated coagulation times (ACT) and heparin concentrations (HC). Combined zero- and first-order elimination was seen in each of the 4 weeks. The half-life of heparin decreased from beginning to end of hemodialysis during each week, with the percentage of decrease from the start of dialysis ranging from 70-74%, indicating concentration-dependent elimination. Since the zero-order component did not appear to be clinically significant, first-order elimination was assumed. A linear decline in ACT over the time of the dialysis period was also seen during each week. A profile of ACT versus HC was generated for each patient as well as for the mean data to assess the relationship of HC to response. An excellent correlation was found for both individual patient data and mean data. In the third week the patients were randomized to receive standard treatment or an individualized dose. They were then crossed over to the opposite group in the fourth week to see if this relationship between ACT and HC would be useful in predicting heparin dose. These profiles were used to individualize the dose during either the third or fourth week of the study. No significant differences were noted between actual and predicted ACT. A significant degree of interpatient variability was demonstrated.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2235671

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  5 in total

1.  Correlates and variance decomposition analysis of heparin dosing for maintenance hemodialysis in older US patients.

Authors:  Jenny I Shen; Maria E Montez-Rath; Aya A Mitani; Kevin F Erickson; Wolfgang C Winkelmayer
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-02-18       Impact factor: 2.890

2.  Anticoagulation in patients with acute kidney injury undergoing kidney replacement therapy.

Authors:  Rupesh Raina; Ronith Chakraborty; Andrew Davenport; Patrick Brophy; Sidharth Sethi; Mignon McCulloch; Timothy Bunchman; Hui Kim Yap
Journal:  Pediatr Nephrol       Date:  2021-10-19       Impact factor: 3.651

Review 3.  Heparin pharmacokinetics and pharmacodynamics.

Authors:  R J Kandrotas
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 4.  Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis.

Authors:  Jenny I Shen; Wolfgang C Winkelmayer
Journal:  Am J Kidney Dis       Date:  2012-05-05       Impact factor: 8.860

5.  Bivalirudin dosing during prolonged intermittent renal replacement therapy: a case report.

Authors:  Nicole M Bohm; Chase Brown
Journal:  J Thromb Thrombolysis       Date:  2020-10-17       Impact factor: 2.300

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.